AR121251A1 - Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida - Google Patents
Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamidaInfo
- Publication number
- AR121251A1 AR121251A1 ARP210100270A ARP210100270A AR121251A1 AR 121251 A1 AR121251 A1 AR 121251A1 AR P210100270 A ARP210100270 A AR P210100270A AR P210100270 A ARP210100270 A AR P210100270A AR 121251 A1 AR121251 A1 AR 121251A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrazole
- methylamino
- pyrimidine
- carboxamide compounds
- compound
- Prior art date
Links
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical class NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en donde R es un compuesto del grupo de fórmulas (2) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975257P | 2020-02-12 | 2020-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121251A1 true AR121251A1 (es) | 2022-05-04 |
Family
ID=74845061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100270A AR121251A1 (es) | 2020-02-12 | 2021-02-02 | Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11634423B2 (es) |
| EP (1) | EP4103565B1 (es) |
| JP (1) | JP7408826B2 (es) |
| KR (1) | KR20220140789A (es) |
| CN (1) | CN115038705B (es) |
| AR (1) | AR121251A1 (es) |
| AU (1) | AU2021219634B2 (es) |
| BR (1) | BR112022015235A2 (es) |
| ES (1) | ES2987748T3 (es) |
| IL (1) | IL295380A (es) |
| MX (1) | MX2022009884A (es) |
| TW (1) | TWI810520B (es) |
| WO (1) | WO2021162942A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2938751T3 (es) * | 2018-09-10 | 2023-04-14 | Lilly Co Eli | Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico |
| TWI800696B (zh) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| US20240335443A1 (en) * | 2021-01-19 | 2024-10-10 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Imidazolopyridazine or pyrazolopyrimidine compounds and compositions |
| WO2023169336A1 (zh) * | 2022-03-09 | 2023-09-14 | 成都科岭源医药技术有限公司 | 一种哒嗪类化合物及其制备方法及用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10223917A1 (de) | 2002-05-29 | 2003-12-11 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| CA2497544C (en) | 2002-09-04 | 2010-11-02 | Schering Corporation | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| CA2497440C (en) | 2002-09-04 | 2011-03-22 | Schering Corporation | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
| KR20050115252A (ko) | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | 피라졸로[1,5-ａ]피리미딘 유도체 |
| TW200745128A (en) | 2005-10-06 | 2007-12-16 | Schering Corp | Pyrazolopyrimidines as protein kinase inhibitors |
| AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
| EP2962566A1 (en) | 2008-10-31 | 2016-01-06 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| RS63320B1 (sr) | 2010-12-08 | 2022-07-29 | The U S A As Represented By The Secretary Department Of Health And Human Services | Supstituisani pirazolopirimidini kao aktivatori glukocerebrozidaze |
| JP6458038B2 (ja) | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| WO2017087590A1 (en) | 2015-11-18 | 2017-05-26 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| KR102531036B1 (ko) | 2016-10-07 | 2023-05-09 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| EP3541817B1 (en) | 2016-11-17 | 2020-12-23 | Bristol-Myers Squibb Company | Imidazopyridazine modulators of il-12, il-23 and/or ifn-alpha |
| CN117946114A (zh) | 2017-07-28 | 2024-04-30 | 武田药品工业株式会社 | Tyk2抑制剂与其用途 |
| ES2938751T3 (es) * | 2018-09-10 | 2023-04-14 | Lilly Co Eli | Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico |
| US11414431B2 (en) | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| TWI800696B (zh) * | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
-
2021
- 2021-02-02 TW TW110103764A patent/TWI810520B/zh not_active IP Right Cessation
- 2021-02-02 AR ARP210100270A patent/AR121251A1/es not_active Application Discontinuation
- 2021-02-05 WO PCT/US2021/016737 patent/WO2021162942A1/en not_active Ceased
- 2021-02-05 CN CN202180014348.4A patent/CN115038705B/zh active Active
- 2021-02-05 MX MX2022009884A patent/MX2022009884A/es unknown
- 2021-02-05 US US17/168,399 patent/US11634423B2/en active Active
- 2021-02-05 BR BR112022015235A patent/BR112022015235A2/pt not_active Application Discontinuation
- 2021-02-05 AU AU2021219634A patent/AU2021219634B2/en not_active Ceased
- 2021-02-05 KR KR1020227031303A patent/KR20220140789A/ko not_active Withdrawn
- 2021-02-05 IL IL295380A patent/IL295380A/en unknown
- 2021-02-05 JP JP2022548684A patent/JP7408826B2/ja active Active
- 2021-02-05 ES ES21709238T patent/ES2987748T3/es active Active
- 2021-02-05 EP EP21709238.6A patent/EP4103565B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7408826B2 (ja) | 2024-01-05 |
| CN115038705B (zh) | 2024-11-08 |
| EP4103565B1 (en) | 2024-05-01 |
| KR20220140789A (ko) | 2022-10-18 |
| CA3167301A1 (en) | 2021-08-19 |
| WO2021162942A1 (en) | 2021-08-19 |
| IL295380A (en) | 2022-10-01 |
| BR112022015235A2 (pt) | 2022-09-20 |
| CN115038705A (zh) | 2022-09-09 |
| US11634423B2 (en) | 2023-04-25 |
| TWI810520B (zh) | 2023-08-01 |
| US20210253581A1 (en) | 2021-08-19 |
| ES2987748T3 (es) | 2024-11-18 |
| TW202144355A (zh) | 2021-12-01 |
| JP2023515774A (ja) | 2023-04-14 |
| AU2021219634B2 (en) | 2024-01-25 |
| MX2022009884A (es) | 2022-08-22 |
| AU2021219634A1 (en) | 2022-09-01 |
| EP4103565A1 (en) | 2022-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121251A1 (es) | Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida | |
| MX2025004220A (es) | Compuestos triciclicos y sus usos | |
| MX2023013892A (es) | Analogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn). | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| MX2022000244A (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas. | |
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| CR20200488A (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| EA200400981A1 (ru) | Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз | |
| ZA202404839B (en) | Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof | |
| YU76401A (sh) | 1-amino triazolo(4,3-a)hinazolin-5-oni i/ili - 5-tioni koji inhibiraju fosfodiesteraze iv | |
| UY27577A1 (es) | Inhibidores de la integrasa del vih | |
| MX2024003130A (es) | Amida 1,4-dihidro-1,6-naftiridina sustituida y uso de la misma. | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| MX2024011951A (es) | Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromaticos | |
| PH12021551957A1 (en) | 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| AR128693A1 (es) | Compuestos antivirales y métodos de elaboración y uso de los mismos | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| MX2024005066A (es) | Compuestos de cd73. | |
| ECSP014079A (es) | Derivados de sulfonamida | |
| AR130303A1 (es) | Compuestos de pirazolilsulfonamida y su uso terapéutico | |
| MX2024006176A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno. | |
| PE20231363A1 (es) | Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias | |
| AR119098A1 (es) | Procedimiento alternativo para la preparación de ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidín-6-il]metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5-a]pirazín-2-il]-carboxílico | |
| WO2007068776B1 (es) | Compuestos antitumorales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |